Pharmaceutical Executive Digital Edition - November 2011

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

The Blitz the Barriers initiative aims to reduce disparities among prostate cancer patients.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.

Valencia will seek to leverage the investment as well as Surek’s leadership experience to drive commercialization of its flagship eCoin system to develop minimally invasive treatments for urinary incontinence.